Clinical Trials Logo

Clinical Trial Summary

Chlordecone is known to induce liver damage in rat and mice but no data exists in human being. However chlordecone was used until 1993 in French West Indies for banana fields, it is important to test what damage can be induced now, for patients exposed. We should consider chlordecone as a potential cofactor of liver fibrosis. So we have chosen to compare two populations of chronic hepatitis B, C or alcoholic, with cirrhosis or without fibrosis due to active hepatitis, who had been exposed to chlordecone.


Clinical Trial Description

Actually, there is no data concerning the impact of chlordecone on the evolution of fibrosis to cirrhosis in chronic hepatitis whereas many studies have been reported liver damage in mice. The goal of this study is to know if co-exposition to chlordecone can induce evolution to cirrhosis in chronic hepatitis due to alcohol or viral hepatitis. At first, we will assess a group of patients with chronic hepatitis B, C or due to alcohol without fibrosis. And they will be compared to patients with cirrhosis exposed to chlordecone too. Patients will be included in 2 hospital centers. All these patients should have an active liver disease. The activity will be defined by histology or elevated transaminases (>2N), fibrosis will be defined by histology or an association of fibroscan and biological markers. Exposition to chlordecone will be evaluated by a blood chlordecone measure for every patient. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03373396
Study type Interventional
Source Centre Hospitalier Universitaire de Pointe-a-Pitre
Contact
Status Completed
Phase N/A
Start date November 8, 2011
Completion date December 21, 2015

See also
  Status Clinical Trial Phase
Recruiting NCT05479721 - LITMUS Imaging Study
Not yet recruiting NCT05120557 - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH N/A
Active, not recruiting NCT05473806 - Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes Phase 4
Not yet recruiting NCT03222167 - Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b Phase 3
Active, not recruiting NCT02344680 - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Not yet recruiting NCT05567614 - Platelets Indices and Its Role to Predict Liver Fibrosis in Patients With Chronic Hepatitis B Infection
Recruiting NCT05402371 - A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis Phase 2
Recruiting NCT02569567 - Comparison of Smart-Shear Wave Elastography and Transient Elastography N/A
Recruiting NCT05855031 - The Liver Care Trial N/A
Completed NCT04493346 - Shear Wave Elastography
Completed NCT04380493 - The Use of the Transient Elastography Paediatric Probe, Compared to the M Probe, Indirect Biomarkers and Histology
Active, not recruiting NCT06315361 - DIAbetes and NAFLD
Not yet recruiting NCT03492879 - Non Invasive Electrical Impedance Technology (EIT) for Diagnosing Liver Diseases Severity N/A
Recruiting NCT04442334 - The European NAFLD Registry
Recruiting NCT05692024 - COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER Phase 1/Phase 2
Completed NCT03659058 - Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR N/A
Recruiting NCT05218538 - Liver Cirrhosis Diagnosis Prioritizing Algorithm Based on Electronic Health Records.
Completed NCT04480710 - A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects Phase 2
Completed NCT00006164 - Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment Phase 3
Recruiting NCT06005012 - Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM Phase 2